Diamyd: Phase 2 trial demonstrates safety, efficacy in type 1 diabetes

By E. Janene Geiss

Philadelphia, Sept. 18 - Diamyd Medical AB said Monday that in a phase 2 trial, two single administrations of Diamyd four weeks apart in 70 patients with recent onset type 1 diabetes demonstrated safety and efficacy in slowing the decline of C-peptide levels after a stimulated meal.

The study also found that Diamyd-treated patients required less insulin than placebo patients. Diamyd-treated patients with disease duration shorter than three months also showed an improved insulin production, according to a news release from the Stockholm biopharmaceutical company.

The data show that Diamyd offers a compelling first-in-class treatment for beta cell preservation in type 1-diabetes, the company said. The findings were presented at the European Diabetes meeting in Copenhagen.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.